Ge Healthcare Bio-Sciences Corp.

Acambis Inc.

Oravax-Merieux Co.

Pnuvax Inc.

Cynthia K Lee

Edward G Hayman

Thomas P Monath

Harold Kleanthous

Patrick M Guertin

Tianxiao Sun

Philip M Levesque

Alicja T Brown

Farshad Guirakhoo

Samuel K Ackerman

Richard A Weltzin

Hitesh Bhagat

Gopalan Soman

William D Thomas

Jacques Pappo

Ilene Sussman

Thomas Ermak

Patricia Londono-Arcila

Donna Freeman

Disclosed herein is a formulation capable of enhancing thermostability and shelf-life of a biological product, the formulation comprising: a tertiary amine N-oxide or a derivative thereof represented by the formulae:  wherein R, R, and Rmay be identical or different and each is a straight or branched lower alkyl group having from 1 to 4 carbon atoms; an inorganic salt; glutamic acid or a salt thereof; a polyol; a physiologically acceptable buffer, and a pharmaceutically acceptable carrier. The tertiary amine N-oxide may be trimethylamine-N-oxide, (CH)NO. The formulation is useful for vaccine stabilization.

Vaccine stabilizer

The invention provides a an inactive, non-replicating vaccine comprising whole virion, chemically inactivated Yellow Fever virus which is inactivated using a method that ensures preservation of critical, neutralizing epitopes. The Yellow Fever virus has been adapted to propagate in cells to higher yields than the unadapted virus. The invention also provides methods for preventing Yellow Fever viral infection.

High yield yellow fever virus strain with increased propagation in cells

Disclosed herein is a formulation capable of enhancing thermostability and shelf-life of a biological product, the formulation comprising: a tertiary amine N-oxide or a derivative thereof represented by the formulae: wherein R, R, and Rmay be identical or different and each is a straight or branched lower alkyl group having from 1 to 4 carbon atoms; an inorganic salt; glutamic acid or a salt thereof; a polyol; a physiologically acceptable buffer, and a pharmaceutically acceptable carrier. The tertiary amine N-oxide may be trimethylamine-N-oxide, (CH)NO. The formulation is useful for vaccine stabilization.

The invention provides a method of immunization against Helicobacter, involving mucosal administration of an attenuated Salmonella vector including a nucleic acid molecule encoding a Helicobacter antigen, and parenteral administration of a soluble Helicobacter antigen, co-administered with a suitable parenteral adjuvant. Also provided by the invention are attenuated Salmonella vectors for use in this method.

Use of Salmonella vectors for vaccination against helicobacter infection

Methods and compositions are provided for prophylactic and antibacterial therapy for Helicobacter, particularly for Helicobacter pylori, infection of humans. The immunogenic composition of the invention is composed of a plurality of multimeric complexes, each complex being composed of recombinant, enzymatically inactive Helicobacter pylori urease. Each multimeric complex is composed of six Urease A subunits and six Urease B subunits. Alternatively, the composition is composed of a mixture of multimeric complexes, wherein each multimeric complex in the mixture is composed of six Urease A subunits and six Urease B subunits or four Urease A subunits and four Urease B subunits.

Multimeric, recombinant urease vaccine

Growing community of inventors

Needham, MA, United States of America

Cynthia K Lee